- Home
- KOSS vs CTOR Comparison
KOSS vs CTOR Comparison
Compare KOSS & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- CTOR
- Stock Information
- Founded
- KOSS 1953
- CTOR 2021
- Country
- KOSS United States
- CTOR United States
- Employees
- KOSS N/A
- CTOR N/A
- Industry
- KOSS Consumer Electronics/Appliances
- CTOR
- Sector
- KOSS Consumer Staples
- CTOR
- Exchange
- KOSS Nasdaq
- CTOR NYSE
- Market Cap
- KOSS 39.9M
- CTOR 47.5M
- IPO Year
- KOSS N/A
- CTOR N/A
- Fundamental
- Price
- KOSS $4.56
- CTOR $0.67
- Analyst Decision
- KOSS
- CTOR Strong Buy
- Analyst Count
- KOSS 0
- CTOR 2
- Target Price
- KOSS N/A
- CTOR $4.50
- AVG Volume (30 Days)
- KOSS 41.8K
- CTOR 3.9M
- Earning Date
- KOSS 05-08-2025
- CTOR 05-21-2025
- Dividend Yield
- KOSS N/A
- CTOR N/A
- EPS Growth
- KOSS N/A
- CTOR N/A
- EPS
- KOSS N/A
- CTOR N/A
- Revenue
- KOSS $12,289,961.00
- CTOR N/A
- Revenue This Year
- KOSS N/A
- CTOR N/A
- Revenue Next Year
- KOSS N/A
- CTOR N/A
- P/E Ratio
- KOSS N/A
- CTOR N/A
- Revenue Growth
- KOSS N/A
- CTOR N/A
- 52 Week Low
- KOSS $2.30
- CTOR $0.55
- 52 Week High
- KOSS $18.73
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- KOSS 46.60
- CTOR N/A
- Support Level
- KOSS $4.21
- CTOR N/A
- Resistance Level
- KOSS $4.69
- CTOR N/A
- Average True Range (ATR)
- KOSS 0.34
- CTOR 0.00
- MACD
- KOSS 0.05
- CTOR 0.00
- Stochastic Oscillator
- KOSS 76.71
- CTOR 0.00
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.